Dual-Action Kinase Inhibitors Control p38α MAP Kinase Threonine Dephosphorylation
Emily Stadnicki,Hannes Ludewig,Ramasamy Prem Kumar,Xicong Wang,Youwei Qiao,Dorothee Kern,Niels Bradshaw
DOI: https://doi.org/10.1101/2024.05.15.594272
2024-05-15
Abstract:Reversible protein phosphorylation directs essential cellular processes including cell-division, cell-growth, cell-death, inflammation, and differentiation. Because of this, small molecule ATP-competitive kinase inhibitors have achieved remarkable clinical success, often achieving target specificity by binding to inactive kinase conformations (type II inhibitors). A key to determining kinase activity, and thus signaling outcome, is the conformational state of kinase activation-loops. Activation-loop phosphorylation is a common regulatory mechanism that promotes kinase activity, while type II inhibitors commonly select inactive activation-loop conformations. We hypothesized that protein phosphatases, which can act as the cell's natural kinase inhibitors, may recognize distinct activation-loop conformations. Using a set of type II inhibitors targeting the MAP kinase p38α, we identified inhibitors that modulate dephosphorylation of the activation-loop phospho-threonine by WIP1. Our X-ray crystal structures of dual phosphorylated p38α bound to the kinase inhibitors pexmetinib, nilotinib and BIRB796 reveal a shared flipped conformation of the activation-loop with a fully accessible phospho-threonine for WIP1. In contrast, our X-ray structure of apo p38α reveals a very different activation-loop conformation with an inaccessible phospho-threonine, thereby explaining increased rate of dephosphorylation upon inhibitor binding. These findings reveal an unexpected dual-action mechanism for kinase inhibitors combining direct active site kinase inhibition with a global decrease in active phosphorylated kinase species, suggesting a new approach to achieve improved potency and specificity.
Biochemistry